Na C /I K symporter (NIS)-mediated radioiodide uptake (RAIU) serves as the basis for targeted ablation of thyroid cancer remnants. However, many patients with thyroid cancer have reduced NIS expression/function and hence do not benefit from radioiodine therapy. microRNA (miR) has emerged as a promising therapeutic target in many diseases; yet, the role of miRs in NISmediated RAIU has not been investigated. In silico analysis was used to identify miRs that may bind to the 3 0 UTR of human NIS (hNIS). The top candidate miR-339-5p directly bound to the 3 0 UTR of hNIS. miR-339-5p overexpression decreased NIS-mediated RAIU in HEK293 cells expressing exogenous hNIS, decreased the levels of NIS mRNA, and RAIU in transretinoic acid/hydrocortisone (tRA/H)-treated MCF-7 human breast cancer cells as well as thyrotropinstimulated PCCl3 rat thyroid cells. Nanostring nCounter rat miR expression assay was conducted to identify miRs deregulated by TGFb, Akti-1/2, or 17-AAG known to modulate RAIU in PCCl3 cells. Among 38 miRs identified, 18 were conserved in humans. One of the 18 miRs, miR-195, was predicted to bind to the 3 0 UTR of hNIS and its overexpression decreased RAIU in tRA/H-treated MCF-7 cells. miR-339-5p was modestly increased in most papillary thyroid carcinomas (PTCs), yet miR-195 was significantly decreased in PTCs. Interestingly, the expression profiles of 18 miRs could be used to distinguish most PTCs from nonmalignant thyroid tissues. This is the first report, to our knowledge, demonstrating that hNIS-mediated RAIU can be modulated by miRs, and that the same miRs may also play roles in the development or maintenance of thyroid malignancy. Accordingly, miRs may serve as emerging targets to halt the progression of thyroid cancer and to enhance the efficacy of radioiodine therapy.
Introduction

Na
C /I K symporter (NIS)-mediated radioiodide uptake (RAIU) in thyroid cells allows for targeted treatment of thyroid cancer. Many patients with advanced thyroid cancer do not benefit from radioiodine therapy due to reduced/ absent expression/function of NIS. microRNA (miR) has emerged as a promising therapeutic target in many diseases (Maqbool & Hussain 2014) . However, the role of miRs in NIS-mediated RAIU has not been investigated. miRs predominantly bind to 3 0 UTR of target genes, resulting in either degradation of target mRNA or inhibition of translation (Krol et al. 2010) . The 3 0 UTR of human NIS (hNIS) is 1296 bp in length, which is about twice as long as the average length of 3 0 UTRs of human genes (Pesole et al. 2000) . Thus, expression of hNIS is likely to be modulated by miRs. Deregulation of miRs in papillary thyroid carcinomas (PTCs) has been reported by several groups (He et al. 2005 , Tetzlaff et al. 2007 , Pallante et al. 2010 , de la Chapelle & Jazdzewski 2011 . As NIS expression is downregulated in most PTCs (Lazar et al. 1999) , it is likely that the upregulated miRs in PTCs may play roles in suppression of NIS. In this study, we aim to identify miRs that modulate the expression of NIS as well as NIS-mediated RAIU. Two different approaches were applied to identify miRs that modulate the expression and function of NIS. In the first approach, in silico analysis was conducted to identify the top candidate miR predicted to bind to the 3 0 UTR of NIS. The effect of this miR on NIS-mediated RAIU was assessed in MCF-7 human breast cancer cells and PCCl3 rat thyroid cells. Direct binding of this miR to the 3 0 UTR of hNIS was verified by luciferase-hNIS-3 0 UTR reporter assay. In the second approach, miRs deregulated by signaling nodes known to modulate NIS-mediated RAIU in PCCl3 cells were identified. Among these deregulated miRs, five miRs were predicted to bind to rat Nis (rNis) 3 0 UTR and one miR was predicted to bind to the 3 0 UTR of hNIS. Their effects on NIS-mediated RAIU were investigated in both MCF-7 and PCCl3 cells. Finally, the expression levels of these miRs in PTC tumors vs their adjacent nonmalignant thyroid tissues were examined in two different cohorts.
Materials and methods
In silico miR prediction tools
To predict miRs that may bind to the 3 0 UTR of hNIS, TargetScan 6.1 (http://www.targetscan.org/), miRanda (http://www.microrna.org/), and miRecords (http://mirecords.biolead.org) were used. To increase robustness, the top predicted miR that had the highest number of binding sites and that was predicted by at least two software packages was selected for further studies. miRanda was used to predict miRs that may bind to the 3 0 UTR of rNis.
TargetScan 6.1 was used to predict the top 100 targets of miR-339-5p and miR-195 in human and rat.
Luciferase reporter assay
Plasmid containing the 3 0 UTR of hNIS cloned downstream of the firefly luciferase CDS and a Renilla luciferase gene as an internal control was purchased from GeneCopoeia, Inc.
(Rockville, MD, USA; pEZX-MT01, ID-HmiT017390-MT01). HeLa cell-line with low endogenous expression of NIS was transfected with this plasmid using Fugene HD (Promega Corporation) for 14 h. The cells were subsequently transfected with 50 mM of synthetic oligo miR-339-5p mimic (Life Technologies; MC12347) or scrambled oligo miR (Negative Control #1) using Lipofectamine 2000 (Life Technologies) for additional 6 h. Luciferase activity was measured in a Glomax-Multi Detection System (Promega Corporation) using a Dual-Luciferase Reporter 1000 Assay System (Promega Corporation). Data are represented as relative fold change of the ratios of firefly luciferase activity normalized to Renilla luciferase activity.
RAIU assay
This assay was performed as described previously (Vadysirisack et al. 2007 ) with 125 I in NaI (80 mCi/mmol).
RAIU in all figures represents fold change in NIS-mediated RAIU values acquired after subtracting nonspecific RAIU values from parallel experiments performed in the presence of 100 mM perchlorate.
Cell culture and reagents
Human embryonic kidney 293 cells (HEK293; ATCC, Manassas, VA, USA, CRL-1573) were cultured in 90% high-glucose DMEM and 10% fetal bovine serum (FBS; Life Technologies). HEK293 cells with low endogenous expression of NIS were transfected with either pcDNA3 vector control or full-length (K375)-hNIS-(3247)/pcDNA3 also known as pcDNA3/FLhNIS, including the complete 5 0 and 3 0 UTRs (Lin 2003) using FuGene 6 transfection reagent (Promega Corporation). Mixed stable clones were selected for 2 weeks using 800 mg/ml G418 (Life Technologies) and then maintained in 400 mg/ml G418. MCF-7 cells (ATCC HTB-22) were cultured in 45% DMEM, 45% F-12, and 10% FBS (Life Technologies). MCF-7 cells were treated with transretinoic acid (tRA; 1 mM)/hydrocortisone (H; 1 mM) (Sigma-Aldrich) for 24 h to induce expression of hNIS. Induction with tRA/H was performed in the presence of 5% charcoal-stripped FBS instead of 10% regular FBS. PCCl3 cells were maintained in 6H media with 5% bovine serum as described by Liu et al. (2012 
miR delivery methods
Lentiviral expression plasmids (System Biosciences) were kind gifts from Dr Lawler. The pCDH-CMV-MCS-EF1-copGFP control plasmid (pCDH) or pCDH/miR-339-5p was packaged into lentiviral particles using HEK293TN cells according to the manufacturer's protocol. HEK293/pcDNA3 and HEK293/FLhNIS cells were transduced using lentiviral particles containing pCDH or pCDH/miR-339-5p. GFP-positive cells were enriched using FACS and cells were allowed to recover for 2 weeks before being used for experiments. Synthetic oligonucleotide miR-339-5p mimic, anti-miR-339-5p (MH12347), or scrambled oligonucleotide miR (10 nM) was transfected into MCF-7 or PCCl3 cells using Lipofectamine RNAiMAX reagent (Life Technologies) for 24 h at the same time as tRA/H treatment or TSH stimulation respectively before the cells were subjected to RAIU assay or RNA extraction.
RNA extraction and quantitative real-time PCR
Total RNA including small RNAs was extracted using the RNeasy Kit (Qiagen) and contaminating DNA was removed by on-column DNase I digestion according to manufacturer's protocol. Quantitative real-time PCR (RT-qPCR) of NIS and GAPDH was performed as described previously (Liu et al. 2012) . Representative data are presented as relative fold changes in NIS mRNA compared with the GAPDH control. 
Next generation sequencing
Small RNA samples from PTC tumors (PTC-T, nZ19), nonmalignant tissue adjacent to but not infiltrated by tumor from the same patient (PTC-N, nZ19), and thyroid tissues from normal individuals (NN, nZ14) were analyzed using a Solid 5500 sequencing platform. The comparison of miRs deregulated between the PTC-T and PTC-N groups was performed using the paired Welch t-test as described previously (Swierniak et al. 2013) . TCGA data (http://cancergenome.nih.gov/) were analyzed using the Wilcoxon signed-rank test. P values of less than 0.05 were considered statistically significant.
Heat map generation
The shortlisted rat miRs from Nanostring analysis were checked for exact sequence matches with human miRs. Expression levels of miRs with exact sequence matches were checked using next generation sequencing (NGS) data from 19 PTC-T/PTC-N pairs and 14 NN samples followed by creation of a heat map using unsupervised clustering. Hierarchical clustering of samples based on expression profiles of selected miRs was performed using Ward's agglomeration method operated on Euclidean distance measures.
Statistical analysis
All experiments had at least two independent trials with three replicates for each experimental group within each trial. For RAIU assay, all the data values were log10 transformed to reduce variance and skewness, and then linear mixed effects models were used to take account of the correlations among observations from the same trial. For RT-qPCR data, linear mixed effects models were used for analysis along with the DDCT method. From the model, all the pre-specified comparisons for each experiment were obtained and adjusted for multiple comparisons using the sequentially rejective Holm's method (Holm 1979 ) to control for type 1 error at 0.05. For luciferase assays, the two sample t-test was performed for comparisons after taking the average of three replicates, and P values of less than 0.05 were considered to be significant. For TCGA data, Pearson's correlation method was used to test the association between the expression of NIS and the selected miRs from patients' tumor samples. Expression of selected miRs from TCGA data were compared between normal and tumor tissues using paired t-tests. SAS v9.2 Software was used for all the analysis (SAS Institute, Inc., Cary, NC, USA).
Results miR-339-5p targets the 3 0 UTR of hNIS and reduces
hNIS-mediated RAIU in HEK293 cells expressing exogenous hNIS
In silico analysis predicted that miR-339-5p has the highest binding score and the highest number of binding sites in the 3 0 UTR of hNIS, i.e. two binding sites at nucleotides 291-297 (TargetScan context score: K0.25 and miRanda mirSVR score: K0.43) and nucleotides 458-464 (TargetScan context score: K0.22 and miRanda mirSVR score: K0.58). As shown in Fig. 1A , overexpression of miR-339-5p resulted in a significant decrease (21%; PZ0.006) in luciferase activity of the luciferase-hNIS-3 0 UTR reporter. Consistent with the luciferase assay, overexpression of miR-339-5p resulted in a significant decrease (36%; PZ0.002) in hNIS-mediated RAIU activity in HEK293 cells stably expressing exogenous hNIS (Fig. 1B) . On the basis of these findings, it is concluded that miR-339-5p directly binds to the 3 0 UTR of hNIS and decreases hNIS-mediated RAIU activity.
miR-339-5p reduces the level of tRA/H-induced hNIS mRNA and hNIS-mediated RAIU in MCF-7 human breast cancer cells
There is no immortalized human thyroid cell-line that consistently expresses endogenous hNIS conferring evident RAIU activity. We choose tRA/H-treated MCF-7 cells to investigate the effect of overexpression of miR-339-5p on the levels of endogenous hNIS mRNA and hNIS-mediated RAIU, as it is well established that tRA/H significantly induces the expression and function of hNIS in MCF-7 cells (Kogai et al. 2000 , Beyer et al. 2011 . As shown in Fig. 2A and B, miR-339-5p overexpression significantly decreased tRA/ H-induced hNIS mRNA levels (26%; P!0.0001) as well as hNIS-mediated RAIU activity (30%; P!0.0001). Note that Fold changes highlighted in bold are significantly upregulated more than 1.4-fold or significantly downregulated more than 1.8-fold. miRs highlighted in italics are conserved between rats and humans. miRs underlined are predicted to bind to the 3 0 UTR of rNis. miRs highlighted in bold are predicted to bind to the 3 0 UTR of hNIS.
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anti-miR-339-5p counteracted the effects of overexpression of miR-339-5p on the expression/function of hNIS, albeit anti-miR-339-5p alone had little effect. As shown in Fig. 2C , miR-339-5p was overexpressed by approximately 1000-fold and this was reduced to approximately 100-fold by anti-miR-339-5p. This is consistent with the notion that anti-miR counteracts the effect of miR most probably by both miR degradation and functional inhibition. Note that the level of endogenous miR-339-5p was not affected by tRA/H treatment, indicating that hNIS expression/function of hNIS induced by tRA/H in MCF-7 cells was not mediated by miR-339-5p. On the basis of these results, it is concluded that expression and function of hNIS was decreased by overexpression of miR-339-5p.
miR-339-5p reduces the levels of TSH-induced rNis mRNA and rNIS-mediated RAIU in PCCl3 rat thyroid cells
As miR-339-5p is 100% conserved between human and rat, we examined the effect of overexpression of miR-339-5p on levels of endogenous rNis mRNA and rNIS-mediated RAIU in PCCl3 rat thyroid cells that express functional rNIS upon stimulation with TSH. The 3 0 UTR of hNIS and the 3 0 UTR of rNis share only 35.2% nucleotide sequence identity and miRanda predicted that miR-339-5p has only one binding site in the 3 0 UTR of rNis on nucleotides 686-691 with a very low score (mirSVR score: K0.02). As shown in Fig. 3A and B, miR-339-5p overexpression resulted in a significant decrease in the levels of TSH-induced rNis mRNA (30%; PZ0.0016) as well as TSH-induced rNIS-mediated RAIU activity (30%; P!0.0001). Note that anti-miR-339-5p counteracted the effects of overexpression of miR-339-5p on the expression/ function of rNIS. As shown in Fig. 3C , miR-339-5p was overexpressed by approximately 200-fold and was reduced to approximately 20-fold by anti-miR-339-5p. TSH had little effect on levels of endogenous miR-339-5p, which is consistent with other findings (Leone et al. 2011 , Akama et al. 2012 ) that the expression of miR-339-5p is not modulated by TSH, the major regulator of the expression and function of NIS. On the basis of these results, it is concluded that the expression and function of rNIS was significantly decreased by overexpression of miR-339-5p.
Several miRs deregulated by signaling nodes that modulate rNIS-mediated RAIU in PCCl3 cells are predicted to bind to the 3 0 UTR of Nis TSH-stimulated RAIU in rat thyroid cells can be modulated by TGFb (Pekary & Hershman 1998 , Nicolussi et al. 2003 , Costamagna et al. 2004 , AKT (Kogai et al. 2008 , Liu et al. 2012 , and HSP90 (Marsee et al. 2004) by modulating the expression of rNIS, the function of rNIS, and iodide efflux respectively. To uncover candidate miRs that modulate rNISmediated RAIU in rat thyroid cells, miRs deregulated by TGFb, Akti-1/2, or 17-AAG in PCCl3 cells were identified (Table 1) . Among 38 miRs identified, miR-218a, miR-425, miR-96, miR-27b, and miR-539 were predicted to bind to the 3 0 UTR of rNis (mirSVR score range: K0.38 to K0.01). Among these five miRs, two miRs were significantly upregulated by TGFb (1.4-and 1.7-fold) indicating their possible roles in the mediation of repression of rNIS by TGFb. As Akti-1/2 and 17-AAG do not modulate expression of rNis, it is puzzling that one out of five miRs predicted to bind to the 3 0 UTR of rNis was upregulated by both 17-AAG and Akti-1/2 (1.4-and 1.6-fold respectively), and three out of five miRs by 17-AAG (1.4-to 1.7-fold). Nevertheless, we examined the direct effects of these five miRs on TSH-stimulated rNIS-mediated RAIU in PCCl3 cells. As shown in Fig. 4A , unlike miR-339-5p, overexpression of these five miRs did not result in a significant decrease in RAIU in PCCl3 cells. miR-339-5p was not included in the list of 38 miRs due to its low expression level in PCCl3 cells, which did not meet the cut-off value of Nanostring analysis. Interestingly, despite its low levels, miR-339-5p was upregulated by TGFb (1.3-fold), indicating that miR-339-5p may mediate the effect of TGFb on rNIS expression. Among 38 rat miRs deregulated by TGFb, Akti-1/2, or 17-AAG in PCCl3 cells, 18 of them have exact sequence matches between human and rat, and miR-195 is predicted to bind the 3 0 UTR of hNIS (mirSVR score: K0.01). Overexpression of miR-195 significantly decreased RAIU by 30% (P!0.0001) which was similar to the effect of miR-339-5p in tRA/H-treated MCF-7 cells (Fig. 4B) . However, miR-195 is not predicted to bind to the 3 0 UTR of rNIS and its overexpression did not significantly decrease (PZ0.2059) rNIS-mediated RAIU in PCCl3 cells (Fig. 4C) . In comparison, overexpression of rno-miR-182 and rno-miR-494, which are predicted to bind to the 3 0 UTR of rNIS (mirSVR score: K0.77 and K0.16 respectively), did significantly decrease rNIS-mediated RAIU in PCCl3 cells (27%; P!0.0001 and 33%; P!0.0001 respectively). On the basis of these results, it is concluded that miR-339-5p modulates the expression of NIS in both human and rat cells, yet miR-195 appears to modulate the expression of NIS in human but not in rat cells, as indicated by its effects on NIS-mediated RAIU activity.
Expression profiles of 18 hsa-miRs distinguish most PTCs from nonmalignant thyroid tissues
Almost all PTCs have reduced NIS-mediated RAIU activity. Accordingly, many signaling pathways driving thyroid tumorigenesis are also known to reduce NIS-mediated RAIU in thyroid. We therefore investigated the expression profiles of the 18 miRs deregulated by TGFb, Akti-1/2, or 17-AAG in 19 PTC-T/PTC-N pairs and 14 NN. As shown in Fig. 5 , the expression profile of these 18 miRs could be used to distinguish most PTC-T samples from PTC-N and NN samples. The fold changes of these 18 miRs in PTC-T compared with PTC-N were examined in the cohort from Medical University of Warsaw (nZ19) as well as from thyroid cancer TCGA database (nZ59). As shown in Table 2 , hsamiR-96 and hsa-miR-27b were significantly upregulated in PTC-T compared with PTC-N in both cohorts. In contrast, hsa-miR-455 and hsa-miR-195 were significantly downregulated in PTC-T compared with PTC-N in both cohorts. As hsa-miR-195 was predicted to bind to the 3 0 UTR of hNIS and its overexpression decreased NIS-mediated RAIU activity, it is surprising that hsa-miR-195 was downregulated rather than upregulated in PTC-T versus PTC-N. Accordingly, miR that plays a role in the development or maintenance of thyroid malignancy may also modulate NIS-mediated RAIU, yet the underlying mechanisms could be distinct and complex in nature.
Discussion
In this study, we have identified miR-339-5p that modulates the levels of NIS mRNA and NIS-mediated RAIU. miR-339-5p directly bound to 3 0 UTR of hNIS and reduced exogenouslyexpressed-hNIS-mediated RAIU in HEK293 cells. miR-339-5p not only reduced tRA/H-induced hNIS mRNA and hNISmediated RAIU in MCF-7 human breast cancer cells but also reduced TSH-induced rNis mRNA and rNIS-mediated RAIU in PCCl3 rat thyroid cells. We have also identified 38 miRs deregulated by reagents known to modulate RAIU in PCCl3 cells, and 18 of them had exact sequence matches between human and rat. miR-195 was predicted to bind to the 3 0 UTR of hNIS but not to the 3 0 UTR of rNis, and its overexpression decreased tRA/H-induced hNIS-mediated RAIU in MCF-7 cells but did not decrease TSH-induced rNIS-mediated RAIU in PCCl3 cells. Interestingly, the 18 miRs deregulated by reagents known to modulate RAIU could be used to distinguish between PTCs from nonmalignant tissues. This finding indicates that miRs that play a role in the development or maintenance of thyroid malignancy may also modulate NIS-mediated RAIU, although the underlying mechanisms could be distinct and complex in nature. miR-339-5p was significantly upregulated in PTC-T by 1.3-fold compared with NN, yet there was no significant difference between PTC-T and PTC-N in the cohort from the Medical University of Warsaw. Similarly, there was no significant difference in the levels of expression of miR-339-5p between PTC-T and PTC-N in the cohort of thyroid cancer from the TCGA database. Pearson's correlation test on 485 PTCs from the TCGA database showed a nonsignificant negative correlation between the levels of miR-339-5p and NIS mRNA (correlation coefficientZK0.063 and PZ0.163). These findings are consistent with the findings that the effect of a single miR on a specific target could be miniscule (Hausser & Zavolan 2014) . In addition, the effect of a given miR on its target can be geneticcontext-dependent, such that its effect on a specific target may not reach statistical significance in a cohort of tumors with various genetic contexts. Indeed, miR-339-5p was one of the top ten upregulated miRs (Nikiforova et al. 2008) in conventional follicular adenomas (13.4-fold), oncocytic follicular adenomas (18.2-fold), oncocytic follicular carcinomas (42.5-fold), and poorly differentiated thyroid carcinomas (6.1-fold). Given the fact that each miR has multiple targets and each target could be modulated by multiple miRs (Hausser & Zavolan 2014) , miRs may exert both direct and indirect effects. In silico prediction scores may not translate to direct binding of miRs to target 3 0 UTRs, and the effects of miRs on the expression or function of target gene may be a consequence of indirect effects. For example, the 5 out of 38 miRs predicted to bind to the 3 0 UTR of rNis had a predicted score range from high to low, yet none of them decreased TSH-stimulated rNIS-mediated RAIU. Conversely, overexpression of miR-339-5p, miR-182, or miR-494 decreased rNISmediated RAIU, yet we were unable to demonstrate their direct binding to the 3 0 UTR or rNis (data not shown). To investigate possible indirect effects of miR-339-5p in the modulation of NIS-mediated RAIU, we analyzed its top 100 predicted targets from TargetScan in both human and rat. Ingenuity pathway analysis of the top 100 targets in humans 1532T  1501T  1771  1718  1644N  1643N  1720  1532N  1677  1772  1501N  1543N  1547N  1543T  1556N  1767  1529N  1510N  1764  1773  1634N  1705  1667  1721  1716  1675  1539N  1508N  1766  1556T  1510T  1508T  1614T  1644T  1643T  1547T  1614T  1529T  1539T  1634T  1541T  1541N PTC-T PTC-N NN Figure 5 Expression profiles of 18 hsa-miRs distinguish most papillary thyroid carcinomas from nonmalignant thyroid tissues. Among the 38 rat miRs deregulated by TGFb, Akti-1/2, or 17-AAG in PCCl3 cells, 18 of them were conserved in humans. The expression levels of the 18 hsa-miRs were extracted from the NGS data from 19 PTC-T/PTC-N pairs and 14 NN. A heat map created by unsupervised clustering using the expression profiles of the 18 hsa-miRs as shown could be used to distinguish most PTC tumors from nonmalignant thyroid tissues.
indicated that MDM2 and SYT2 are involved in RXR pathway activation. As activated RXR is implicated in tRA-induced expression of NIS (Kogai et al. 2000) , overexpression of miR-339-5p may also indirectly suppress tRA-induced NIS by targeting the RXR pathway. Ingenuity pathway analysis of the top 100 targets in rat indicated that BCL2L11, MAGI2, and SOS1 participate in PTEN signaling activation. PTEN inhibition suppresses NIS expression (Dima et al. 2011) ; thus, miR-339-5p overexpression may indirectly suppress NIS expression via PTEN inhibition in rat thyroid cells. miR-195 was significantly downregulated in PTC-T compared with PTC-N in both cohorts examined. Pearson's correlation test on 485 PTCs from TCGA database showed a moderate but significant positive correlation between miR-195 and NIS mRNA levels (coefficientZ0.139 and PZ0.0021). This unexpected finding suggests that miR-195 may modulate other target(s) that counteract it's repression of NIS mRNA, and these target(s) are present in thyroid tumors but absent in tRA/H-treated MCF-7 cells. Alternatively, repression of hNIS mRNA by miR-195 could be overridden by other factors unique to thyroid tumors. To investigate possible indirect effects of miR-195 in the modulation of NIS-mediated RAIU, we examined its top 100 targets in humans. Ingenuity pathway analysis of the top 100 targets in humans indicated that AKT3, EIF4G2, INSR, and RPS6KA6 are involved in activation of the mTOR pathway and RAB9B and RasGEF1B are involved in activation of the RAS pathway. Activation of the PI3K/AKT/mTOR pathway (Ohashi et al. 2009) The signaling nodes of TGFb, AKT, or HSP90 are known to play a role in progression of thyroid tumors, thus it is not surprising that 18 out of 38 miRs deregulated by TGFb, Akti-1/2, or 17-AAG could be used to separate PTC-T from PTC-N. The listed 18 miRs as a group were not previously reported to be important players in thyroid tumorigenesis, possibly due to their relatively low expression levels. miR-195 (T/N ratioZ0.51) was recently shown to target ZNF367, an important regulator of cancer progression (Jain et al. 2014) . miR-218 and miR-30c (Tetzlaff et al. 2007 ) as well as miR-148 and miR-15b (Pallante et al. 2006) have been reported to be downregulated in PTCs versus nonmalignant thyroid tissues. miR-29 a/b/c was upregulated in PTC-T versus PTC-N (He et al. 2005) . The T/N values of these miRs, except miR-29c, are consistent with results described in previous publications. Finally, it is interesting to note that 11 out of 38 miRs that we identified were among those miRs reported to be downregulated by 24 h TSH stimulation in FRTL-5 cells (Akama et al. 2012) . The finding that 6 out of 11 TSH-modulated miRs were upregulated by TGFb 
